Amgen Cash Flow from Operating Activities 2010-2025 | AMGN

Amgen cash flow from operating activities for the twelve months ending June 30, 2025 was $23.271B, a 14.97% increase year-over-year.

  • Amgen annual cash flow from operating activities for 2024 was $11.49B, a 35.64% increase from 2023.
  • Amgen annual cash flow from operating activities for 2023 was $8.471B, a 12.86% decline from 2022.
  • Amgen annual cash flow from operating activities for 2022 was $9.721B, a 4.97% increase from 2021.

Amgen Cash Flow from Operating Activities 2010-2025 | AMGN

  • Amgen annual cash flow from operating activities for 2024 was $11.49B, a 35.64% increase from 2023.
  • Amgen annual cash flow from operating activities for 2023 was $8.471B, a 12.86% decline from 2022.
  • Amgen annual cash flow from operating activities for 2022 was $9.721B, a 4.97% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$245.5B
Gilead Sciences (GILD)$146.9B
Vertex Pharmaceuticals (VRTX)$100.7B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.1B
GSK (GSK)$80.2B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.8B
Argenex SE (ARGX)$40B
BioNTech SE (BNTX)$27.3B
Insmed (INSM)$27B
Royalty Pharma (RPRX)$21.2B
Biogen (BIIB)$20.3B
Incyte (INCY)$17B
Illumina (ILMN)$15.4B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15B
Ascendis Pharma (ASND)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$11B
Moderna (MRNA)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Halozyme Therapeutics (HALO)$7.9B
Guardant Health (GH)$7.3B